Atlas Trials

Evaluate the Safety and Efficacy of Autologous Tumor-infiltrating Lymphocyte in Patients With Refractory Melanoma Who Failed to Immune Checkpoint Inhibitors

Clinical trial NCT07028008 · NOT_YET_RECRUITING

Trial details

NCT number
NCT07028008
Sponsor
Samsung Medical Center
Status
NOT_YET_RECRUITING
Phase
Not Applicable
Study type
INTERVENTIONAL
Melanoma
Start date
2025-10-15
Primary completion
2027-05-28
Enrollment
9

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.